Cuenca J, Hanmandlu A, Wegner R, Botdorf J, Tummala S, Iliescu C
BMC Anesthesiol. 2023; 23(1):310.
PMID: 37700240
PMC: 10496364.
DOI: 10.1186/s12871-023-02257-z.
Seligman C, Chang Y, Luo J, Garden O
Front Neurol. 2023; 13:1004810.
PMID: 36698907
PMC: 9868566.
DOI: 10.3389/fneur.2022.1004810.
Soman B, Dias M, Rizvi S, Kardos A
BMJ Case Rep. 2023; 15(12).
PMID: 36593626
PMC: 9743272.
DOI: 10.1136/bcr-2022-251966.
Cozma A, Sporis N, Lazar A, Buruiana A, Ganea A, Malinescu T
Int J Mol Sci. 2022; 23(18).
PMID: 36142866
PMC: 9502843.
DOI: 10.3390/ijms231810948.
Findlay S, Plummer R, Plummer C
Br J Cardiol. 2022; 27(1):02.
PMID: 35747420
PMC: 8793930.
DOI: 10.5837/bjc.2020.002.
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O
Vaccines (Basel). 2022; 10(4).
PMID: 35455289
PMC: 9031363.
DOI: 10.3390/vaccines10040540.
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.
Ruggiero R, Stelitano B, Fraenza F, Mauro G, Scavone C, Sportiello L
Front Oncol. 2022; 12:824511.
PMID: 35372076
PMC: 8964934.
DOI: 10.3389/fonc.2022.824511.
Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R, Iwai Y, Yamazaki T, Takahashi H, Hori Y, Fukushima K
Intern Med. 2022; 61(19):2973-2979.
PMID: 35314545
PMC: 9593150.
DOI: 10.2169/internalmedicine.8772-21.
A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.
Komatsu M, Hirai M, Kobayashi K, Hashidate H, Fukumoto J, Sato A
BMC Gastroenterol. 2021; 21(1):333.
PMID: 34445963
PMC: 8393464.
DOI: 10.1186/s12876-021-01904-4.
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R, Katel A, Massarelli E, Villaflor V, Sun V, Salgia R
Oncologist. 2021; 26(12):1052-1061.
PMID: 34378270
PMC: 8649039.
DOI: 10.1002/onco.13931.
Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
Matzen E, Bartels L, Logstrup B, Horskaer S, Stilling C, Donskov F
Cardiooncology. 2021; 7(1):27.
PMID: 34365980
PMC: 8351114.
DOI: 10.1186/s40959-021-00114-x.
Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management.
Zarifa A, Kim J, Lopez-Mattei J, Palaskas N, Iliescu C, Kim P
Korean Circ J. 2021; 51(7):579-597.
PMID: 34227272
PMC: 8263294.
DOI: 10.4070/kcj.2021.0089.
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.
Huang Y, Chen Y, Lin W, Su W, Sun Y
Front Neurol. 2020; 11:634.
PMID: 32765397
PMC: 7378376.
DOI: 10.3389/fneur.2020.00634.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham C, Visser K, Leipe J, Schulze-Koops H
Ann Rheum Dis. 2020; 80(1):36-48.
PMID: 32327425
PMC: 7788064.
DOI: 10.1136/annrheumdis-2020-217139.
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen H, Guz-Montgomery K, Saha D
Cells. 2020; 9(2).
PMID: 32050597
PMC: 7072539.
DOI: 10.3390/cells9020400.
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
Atallah-Yunes S, Kadado A, Kaufman G, Hernandez-Montfort J
J Cancer Res Clin Oncol. 2019; 145(6):1527-1557.
PMID: 31028541
DOI: 10.1007/s00432-019-02927-x.
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.
Agrawal N, Khunger A, Vachhani P, Colvin T, Hattoum A, Spangenthal E
Case Rep Oncol. 2019; 12(1):260-276.
PMID: 31011325
PMC: 6465686.
DOI: 10.1159/000498985.
